NovaBridge Biosciences Stock-Based Compensation
NovaBridge Biosciences (NBP) reported Stock-Based Compensation of $5.97 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-04-07
- NovaBridge Biosciences share-based payment arrangement, noncash expense for the quarter ending 2020-12-31 was 100.89M CNY, a 1008780.00% increase year-over-year.
- NovaBridge Biosciences share-based payment arrangement, noncash expense for the quarter ending 2019-12-31 was 10.00K CNY.
CNY
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | 193.00M CNY 20-F · filed 2024-04-30 | |||
| 2022-12-31 | 357.15M CNY 20-F · filed 2024-04-30 | |||
| 2022-06-30 | 196.94M CNY 6-K · filed 2022-11-10 | |||
| 2021-12-31 | 608.61M CNY 20-F · filed 2024-04-30 | |||
| 2021-06-30 | 334.72M CNY 6-K · filed 2022-11-10 | |||
| 2020-12-31 | 100.89M CNY derived: 20-F 12 month − 6-K 9 month · filed 2023-05-01 | 493.46M CNY 20-F · filed 2023-05-01 | ||
| 2020-09-30 | 392.58M CNY 6-K · filed 2021-02-05 | |||
| 2019-12-31 | 10.00K CNY derived: 20-F 12 month − 6-K 9 month · filed 2022-04-29 | 366.89M CNY 20-F · filed 2022-04-29 | ||
| 2019-09-30 | 366.88M CNY 6-K · filed 2021-02-05 | |||
| 2018-12-31 | 3.52M CNY 20-F · filed 2021-04-28 | |||
| 2017-12-31 | 7.04M CNY 20-F · filed 2020-04-29 |
USD
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $3.94M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $5.40M derived: sum of 2 quarters · filed 2026-04-07 | $5.97M 20-F · filed 2026-04-07 | ||
| 2025-09-30 | $1.46M derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $2.03M 6-K · filed 2025-12-18 | |||
| 2025-06-30 | $572.00K 6-K · filed 2025-10-06 | ||||
| 2024-12-31 | $824.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $1.14M derived: sum of 2 quarters · filed 2026-04-07 | -$1.95M 20-F · filed 2026-04-07 | ||
| 2024-09-30 | $318.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | -$2.77M 6-K · filed 2025-12-18 | |||
| 2024-06-30 | -$3.09M 6-K · filed 2025-10-06 | ||||
| 2023-12-31 | $10.24M 20-F · filed 2026-04-07 | $27.18M 20-F · filed 2024-04-30 | |||
| 2022-12-31 | $13.15M 20-F · filed 2025-04-03 | $51.78M 20-F · filed 2023-05-01 | |||
| 2022-06-30 | $29.40M 6-K · filed 2022-11-10 | ||||
| 2021-12-31 | $95.50M 20-F · filed 2022-04-29 | ||||
| 2020-12-31 | $17.81M derived: 20-F 12 month − 6-K 9 month · filed 2021-04-28 | $75.63M 20-F · filed 2021-04-28 | |||
| 2020-09-30 | $57.82M 6-K · filed 2021-02-05 | ||||
| 2019-12-31 | $52.70M 20-F · filed 2020-04-29 |